A Case of Acneiform Eruption and Paronychia Occurring after Use of Erlotinib (Tarceva(R)).
- Author:
Je Ho YEON
1
;
Seong Uk MIN
;
Dong Hun LEE
;
Yu Sung CHOI
;
Dae Hun SUH
Author Information
1. Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea. daehun@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Acneiform eruption;
Erlotinib;
Paronychia
- MeSH:
Acneiform Eruptions*;
Aged;
Anti-Bacterial Agents;
Carcinoma, Non-Small-Cell Lung;
Erythema;
Humans;
Lung Neoplasms;
Pancreatic Neoplasms;
Paronychia*;
Pyridoxine;
Receptor, Epidermal Growth Factor;
Signal Transduction;
Skin;
Suppuration;
Erlotinib Hydrochloride
- From:Korean Journal of Dermatology
2007;45(11):1180-1182
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Erlotinib (Tarceva(R)) is a new anti-cancer agent which acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell lung cancer and pancreatic cancer. We report a case of acneiform eruption and paronychia induced by erlotinib in a 69-year-old man. The patient visited our clinic with multiple erythematous papules and pustules on the face, periungual erythema and pus discharge, xerosis, fissures on the sole. He had taken erlotinib for the treatment of recurred lung cancer for 4 weeks. The skin lesions were partially improved with oral pyridoxine, corticosteroid and topical antibiotics.
